Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 11 Desmoid Tumors 6 Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Leukemia 1 Hematologic Diseases 1 HIV Infections 1 Granulosa cell tumor of the ovary 1 Corneal Diseases 1 Breast Neoplasms 1 Breast Cancer Metastatic 1 Blood Protein Disorders 1 Advanced Solid Tumors 1 AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 594 Paclitaxel 561 Cyclophosphamide 545 Docetaxel 478 Capecitabine 387 Letrozole 350 Fulvestrant 310 Doxorubicin 285 Carboplatin 277 Tamoxifen 257 Anastrozole 219 exemestane 211 Epirubicin 210 Radiotherapy 197 Bevacizumab 189 pertuzumab 175 Gemcitabine 163 Vinorelbine 162 pembrolizumab 161 Lapatinib 161 palbociclib 152 Exercise 132 Fluorouracil 118 Albumin-Bound Paclitaxel 116 eribulin 108 Magnetic Resonance Spectroscopy 108 130-nm albumin-bound paclitaxel 107 Everolimus 103 Taxes 96 Cisplatin 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × nirogacestat × Clear all

NCT02338531 2016-04-29

RHEA

Jules Bordet Institute

Phase 2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡